Quantitative Systematic Strategies LLC Blueprint Medicines Corp Transaction History

Quantitative Systematic Strategies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 16, 2021	SELL	$80.98 - $109.47 $485,070 - $655,725	-5,990 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$82.78 - $101.0 $567,291 - $692,153	-6,853 Reduced 53.36%	5,990 $527,000
Q1 2021 May 06, 2021	BUY	$90.71 - $108.28 $373,362 - $445,680	4,116 Added 47.16%	12,843 $1.25 Million
Q4 2020 Feb 09, 2021	BUY	$92.08 - $124.48 $32,964 - $44,563	358 Added 4.28%	8,727 $979,000
Q3 2020 Nov 09, 2020	SELL	$66.45 - $92.7 $301,417 - $420,487	-4,536 Reduced 35.15%	8,369 $776,000
Q2 2020 Aug 04, 2020	BUY	$57.09 - $79.27 $436,395 - $605,939	7,644 Added 145.3%	12,905 $1.01 Million
Q1 2020 May 06, 2020	BUY	$48.11 - $82.22 $19,340 - $33,052	402 Added 8.27%	5,261 $308,000
Q4 2019 Feb 11, 2020	SELL	$66.73 - $82.59 $429,207 - $531,218	-6,432 Reduced 56.97%	4,859 $389,000
Q3 2019 Nov 07, 2019	BUY	$72.9 - $101.41 $54,675 - $76,057	750 Added 7.12%	11,291 $830,000
Q2 2019 Jul 25, 2019	BUY	$73.54 - $97.8 $775,185 - $1.03 Million	10,541 New	10,541 $994,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Quantitative Systematic Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on Quantitative Systematic Strategies LLC with notifications on news.